2025年4月24日 周四
首页 > 按月查看>2020年第9月 >809-814
PDF 导出
Klotho与心血管疾病的关系及其生物学机制
作者:
作者单位:

(中国人民解放军陆军军医大学第二附属医院心内科,重庆市 400037)

作者简介:

毛琦,硕士,主治医师,研究方向为血管生物学及冠心病防治,E-mail为holygeneral1214@163.com。通信作者赵晓辉,博士,副主任医师,博士研究生导师,研究方向为冠心病防治及介入治疗,E-mail为doctorzhaoxiaohui@yahoo.com。

基金项目:

国家自然科学基金面上项目(81670428)


Association of Klotho with cardiovascular diseases and its biological mechanisms
Author:
Affiliation:

Department of Cardiology, the Second Affiliated Hospital of Army Medical University, PLA, Chongqing 400037, China)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • | |
    摘要:

    Klotho是重要的内源性多效蛋白,参与衰老和钙磷代谢等病理生理过程,与心血管疾病密切相关。近期的临床研究发现低水平的Klotho与更多的心血管危险因素关联,并能预测心血管疾病的发病风险和不良预后；基础研究也表明Klotho在维持血管稳态和正常心功能中发挥了至关重要的作用。Klotho可以促进一氧化氮(NO)的生成,抑制炎症因子和黏附分子的表达,介导抗氧化、抗凋亡、抗衰老的生物学效应,延缓动脉粥样硬化及血管钙化,并抑制心肌肥厚和纤维化。Klotho或可作为一个新的干预靶点,为心血管疾病的防治提供新的思路。文章就Klotho与心血管疾病的关系及其潜在的生物学机制做一综述。

    Abstract:

    Klotho is an important endogenous pluripotent protein involved in pathophysiological processes such as aging and calcium/phosphorus metabolism, which is closely correlated with cardiovascular diseases. Recent clinical studies have found that low levels of Klotho expression are associated with more cardiovascular risk factors and predict cardiovascular risk; Basic studies have also shown that Klotho plays a pivotal role in maintaining vascular homeostasis and heart function. Klotho can promote nitric oxide (NO) production, reduce the expression of inflammatory factors and adhesion molecules, mediate the biological effects of anti-oxidation, anti-apoptosis, and anti-aging, alleviate atherosclerosis and vascular calcification, and inhibit cardiac hypertrophy and fibrosis. Klotho may serve as a new interventional target and provide new insights for the prevention and treatment of cardiovascular diseases. This review aims to summarize the association of Klotho with cardiovascular diseases and its underlying biological mechanisms.

    参考文献
    [1] Bettinger N, Palmerini T, Caixeta A, et al.Risk stratification of patients undergoing medical therapy after coronary angiography.Eur Heart J, 6,7(40):3103-3110.
    [2] Roffi M, Patrono C, Collet J, et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J, 6,7(3):267-315.
    [3] Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, et al.Novel therapeutic targets of metformin:metabolic syndrome and cardiovascular disease.Expert Opin Ther Targets, 5,9(7):869-877.
    [4] Eggers KM, Kempf T, Venge P, et al.Improving long-term risk prediction in patients with acute chest pain:The Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers.Am Heart J, 0,0(1):88-94.
    [5] Ridker PM, Everett BM, Thuren T, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med, 7,7(12):1119-1131.
    [6] Xu Y, Sun Z.Molecular basis of Klotho:from gene to function in aging.Endocr Rev, 5,6(2):174-193.
    [7] Kurosu H.Suppression of aging in mice by the hormone Klotho.Science, 5,9(5742):1829-1833.
    [8] Vervloet MG, Adema AY, Larsson TE, et al.The role of Klotho on vascular calcification and endothelial function in chronic kidney disease.Semin Nephrol, 4,4(6):578-585.
    [9] Wang Y, Sun Z.Current understanding of Klotho.Ageing Res Rev, 9,8(1):43-51.
    [10] Harvey A, Montezano AC, Lopes RA, et al.Vascular fibrosis in aging and hypertension:molecular mechanisms and clinical implications.Can J Cardiol, 6,2(5):659-668.
    [11] Kamari Y, Fingrut O, Shaish A, et al.The effect of Klotho treatment on atherogenesis, blood pressure, and metabolic parameters in experimental rodent models.Horm Metab Res, 6,8(3):196-200.
    [12] Kuro-O M.Klotho as a regulator of oxidative stress and senescence.Biol Chem, 8,9(3):233-241.
    [13] Yamamoto M, Clark J D, Pastor JV, et al.Regulation of oxidative stress by the anti-aging hormone Klotho.J Biol Chem, 5,0(45):38029-38034.
    [14] Semba RD, Cappola AR, Sun K, et al.Plasma Klotho and cardiovascular disease in adults.J Am Geriatr Soc, 1,9(9):1596-1601.
    [15] Martín-Núez E.Implications of Klotho in vascular health and disease.World J Cardiol, 4,6(12):1262.
    [16] Navarro-González JF, Donate-Correa J, Muros De Fuentes M, et al.Reduced Klotho is associated with the presence and severity of coronary artery disease.Heart, 3,0(1):34-40.
    [17] Kitagawa M, Sugiyama H, Morinaga H, et al.A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.PLoS One, 3,8(2):e56695.
    [18] Brandenburg VM, Kleber ME, Vervloet MG, et al.Soluble Klotho and mortality:the ludwigshafen risk and cardiovascular health study.Atherosclerosis, 5,2(2):483-489.
    [19] Seiler S, Rogacev KS, Roth HJ, et al.Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.Clin J Am Soc Nephrol, 4,9(6):1049-1058.
    [20] Ikushima M, Rakugi H, Ishikawa K, et al.Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells.Biochem Biophys Res Commun, 6,9(3):827-832.
    [21] Saito Y, Yamagishi T, Nakamura T, et al.Klotho protein protects against endothelial dysfunction.Biochem Biophys Res Commun, 8,8(2):324-329.
    [22] Saito Y, Nakamura T, Ohyama Y, et al.In Vivo Klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome.Biochem Biophys Res Commun, 0,6(2):767-772.
    [23] Balasubramanian P, Longo VD.Linking Klotho, Nrf2, MAP kinases and aging.Aging, 0,2(10):632-633.
    [24] Yao Y, Wang Y, Zhang Y, et al.Klotho ameliorates oxidized low density lipoprotein (ox-LDL)-induced oxidative stress via regulating LOX-1 and PI3K/Akt/eNOS pathways.Lipids Health Dis, 7,6(1):77.
    [25] Wang Y, Kuro-O M, Sun Z.Klotho gene delivery suppresses Nox2 expression and attenuates oxidative stress in rat aortic smooth muscle cells via the cAMP-PKA pathway.Aging Cell, 2,1(3):410-417.
    [26] Sun S, Cheng B, Sun PG, et al.RTEF-1 protects against oxidative damage induced by H2O2 in human umbilical vein endothelial cells through Klotho activation.Exp Bio Med, 5,0(12):1606-1613.
    [27] Six I, Okazaki H, Gross P, et al.Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium.PLoS One, 4,9(4):e93423.
    [28] Maekawa Y, Ishikawa K, Yasuda O, et al.Klotho suppresses TNF-α-induced expression of adhesion molecules in the endothelium and attenuates NF-κB activation.Endocrine, 9,5(3):341-346.
    [29] Xia W, Zhang A, Jia Z, et al.Klotho contributes to pravastatin effect on suppressing IL-6 production in endothelial cells.Mediators Inflamm, 6,6:1-6.
    [30] Olejnik A, Franczak A, Krzywonos-Zawadzka A, et al.The biological role of Klotho protein in the development of cardiovascular diseases.Biomed Res Int, 8,8:1-17.
    [31] Unger RH.Klotho-induced insulin resistance:a blessing in disguise?.Nat Med, 6,2(1):56-57.
    [32] Sopjani M, Rinnerthaler M, Kruja J, et al.Intracellular signaling of the aging suppressor protein Klotho.Curr Mol Med, 5,5(1):27-37.
    [33] Mencke R, Hillebrands JL.The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology.Ageing Res Rev, 7,5:124-146.
    [34] Hu MC, Shi M, Zhang J, et al.Klotho deficiency causes vascular calcification in chronic kidney disease.J Am Soc Nephrol, 1,2(1):124-136.
    [35] Chen T, Kuro-O M, Chen C, et al.The secreted Klotho protein restores phosphate retention and suppresses accelerated aging in Klotho mutant mice.Eur J Pharmacol, 3,8(1-3):67-73.
    [36] Lau WL, Leaf EM, Hu MC, et al.Vitamin D receptor agonists increase Klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.Kidney Int, 2,2(12):1261-1270.
    [37] Donate-Correa J, Mora-Fernández C, Martínez-Sanz R, et al.Expression of FGF23/KLOTHO system in human vascular tissue.Int J Cardiol, 3,5(1):179-183.
    [38] Lim K, Lu T, Molostvov G, et al.Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.Circulation, 2,5(18):2243-2255.
    [39] Scialla JJ, Lau WL, Reilly MP, et al.Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.Kidney Int, 3,3(6):1159-1168.
    [40] Lindberg K, Olauson H, Amin R, et al.Arterial Klotho expression and FGF23 effects on vascular calcification and function.PLoS One, 3,8(4):e60658.
    [41] Fang Y, Ginsberg C, Sugatani T, et al.Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.Kidney Int, 4,5(1):142-150.
    [42] Jimbo R, Shimosawa T.Cardiovascular risk factors and chronic kidney disease-FGF23:a key molecule in the cardiovascular disease.Int J Hypertens, 4,4:1-9.
    [43] Hui H, Zhai Y, Ao L, et al.Klotho suppresses the inflammatory responses and ameliorates cardiac dysfunction in aging endotoxemic mice.Oncotarget, 7,8(9):15663.
    [44] Krause M, Heck TG, Bittencourt A, et al.The chaperone balance hypothesis:the importance of the extracellular to intracellular HSP70 ratio to inflammation-driven type 2 diabetes, the effect of exercise, and the implications for clinical management .Mediators Inflamm, 5,5:1-12.
    [45] Guo Y, Zhuang X, Huang Z, et al.Klotho protects the heart from hyperglycemia-induced injury by inactivating ROS and NF-kappaB-mediated inflammation both in vitro and in vivo.Biochim Biophys Acta Mol Basis Dis, 8,4(1):238-251.
    [46] Wu X, Eder P, Chang B, et al.TRPC channels are necessary mediators of pathologic cardiac hypertrophy.Proc Natl Acad Sci USA, 0,7(15):7000-7005.
    [47] Bush EW, Hood DB, Papst PJ, et al.Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling.J Bio Chem, 6,1(44):33487-33496.
    [48] Sabourin J, Robin E, Raddatz E.A key role of TRPC channels in the regulation of electromechanical activity of the developing heart.Cardiovasc Res, 1,2(2):226-236.
    [49] Yang K, Wang C, Nie L, et al.Klotho protects against indoxyl sulphate-induced myocardial hypertrophy.J Am Soc Nephrol, 5,6(10):2434-2446.
    [50] Weber KT, Sun Y, Gerling IC, et al.Regression of established cardiac fibrosis in hypertensive heart disease.Am J Hypertens, 7,0(11):1049-1052.
    [51] Liu X, Chen Y, Mccoy CW, et al.Differential regulatory role of soluble Klothos on cardiac fibrogenesis in hypertension.Am J Hypertens, 6,9(10):1140-1147.
    [52] van den Borne SW, Diez J, Blankesteijn WM, et al.Myocardial remodeling after infarction:the role of myofibroblasts.Nat Rev Cardiol, 0,7(1):30-37.
    [53] Fan J, Sun Z.The Antiaging gene Klotho regulates proliferation and differentiation of adipose-derived stem cells.Stem Cells, 6,4(6):1615-1625.
    [54] Jia G, Demarco VG, Sowers JR.Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.Nat Rev Endocrinol, 6,2(3):144-153.
    引证文献
引用本文

毛琦,王玉清,李佑美,赵晓辉. Klotho与心血管疾病的关系及其生物学机制[J].中国动脉硬化杂志,2020,28(9):809~814.

复制
分享
文章指标
  • 点击次数:533
  • 下载次数: 872
历史
  • 收稿日期:2019-10-10
  • 最后修改日期:2020-01-16
  • 在线发布日期: 2020-10-28

您是本站第 4825466 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2025 网站版权所有